Becton Dickinson (BDX-N) Stock Predictions - Stockchase
WATCH LIST
48
Becton Dickinson (BDX-N)

ON STOCKCHASE SINCE May 2003

disposable medical supplies

biotechnology/pharmaceutical

Becton Dickinson

BDX-N

31 watching          
Join the Discussion

Becton Dickinson (BDX-N) SAVE Feb, 16, 2019, 5:35 am

248.34 3.83 (1.57%)

About Becton Dickinson (BDX-N)

Becton, Dickinson and Company is an American medical technology company that manufactures and sells medical devices, instrument systems, and reagents. More at Wikipedia

What the experts are saying about BDX-N



  • All
  • Filtered
Signal Opinion Expert
DON'T BUY
Becton Dickinson(BDX-N) 

January 31, 2019

They made a huge acquisition a few years ago and took on debt. They are OK financially but they overpaid for the company. He prefers other areas in the Health Care space. It is a big question mark how they integrate this company.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
They made a huge acquisition a few years ago and took on debt. They are OK financially but they overpaid for the company. He prefers other areas in the Health Care space. It is a big question mark how they integrate this company.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Lorne Steinberg

President , Lorne Steinberg Weal...

Price Price
$249.460
Owned Owned
Unknown

PAST TOP PICK
Becton Dickinson(BDX-N) 

January 22, 2019

(A Top Pick Jan 04/18, Up 10%) They had a tremendous catalogue of hospital supplies, mostly one-time use items. Every hospital uses their stuff.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
(A Top Pick Jan 04/18, Up 10%) They had a tremendous catalogue of hospital supplies, mostly one-time use items. Every hospital uses their stuff.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
David Baskin

President, Baskin Wealth Manage...

Price Price
$239.190
Owned Owned
Yes

HOLD
Becton Dickinson(BDX-N) 

January 17, 2019

Has been around for 100 years. Valuation is 15x earnings for 2021. Stock jumped today. Big free cash flow company. Made an acquisition of Bard, another free cash flow giant, so they're paying down debt quickly. So they'll have cash to make acquisitions or grow dividend. In comparing retail to medical devices, he'd always pick the medical device company.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Has been around for 100 years. Valuation is 15x earnings for 2021. Stock jumped today. Big free cash flow company. Made an acquisition of Bard, another free cash flow giant, so they're paying down debt quickly. So they'll have cash to make acquisitions or grow dividend. In comparing retail to medical devices, he'd always pick the medical device company.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
David Driscoll

President , Liberty Internationa...

Price Price
$236.110
Owned Owned
Yes

TOP PICK
Becton Dickinson(BDX-N) 

January 17, 2019

The oldest manufacturer of syringes and other medical devices. There is good growth in emerging countries. They will pay down debt and have attractive dividend growth. (Analysts’ price target is $263.10)
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
The oldest manufacturer of syringes and other medical devices. There is good growth in emerging countries. They will pay down debt and have attractive dividend growth. (Analysts’ price target is $263.10)
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Michael Simpson

Senior Vic, Sentry Investments...

Price Price
$236.110
Owned Owned
Yes

HOLD
Becton Dickinson(BDX-N) 

January 7, 2019

Has owned for a while. One of the more defensive companies you can own. Medical things you can only use once. Sells a suite of products and software to hospitals. Lots of EM opportunities. Still has to pay down debt from an acquisition, but but in 12-18 months should be ready for another. Good place to be with aging demographics, especially in US.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Has owned for a while. One of the more defensive companies you can own. Medical things you can only use once. Sells a suite of products and software to hospitals. Lots of EM opportunities. Still has to pay down debt from an acquisition, but but in 12-18 months should be ready for another. Good place to be with aging demographics, especially in US.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Barry Schwartz

CIO & Port, Baskin Wealth Manage...

Price Price
$218.640
Owned Owned
Yes

WATCH
Becton Dickinson(BDX-N) 

December 3, 2018

Merely an okay last quarter with cost increases and more debt after an acquisition. Resin cost inputs are worth watching. Trades at 18x earnings. Watching this closely. Neutral.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Merely an okay last quarter with cost increases and more debt after an acquisition. Resin cost inputs are worth watching. Trades at 18x earnings. Watching this closely. Neutral.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Paul Macdonald

Chief Inve, Harvest Portfolios G...

Price Price
$252.560
Owned Owned
No

PAST TOP PICK
Becton Dickinson(BDX-N) 

November 12, 2018

(A Top Pick Nov 07/17, Up 10%) Their big thing is drug delivery equipment. They have a lot of things going for them. They had a messy quarter. It is why he prefers to use ETFs for this. It was not a small pull back for them. The acquisition gives them some synergy on costs.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
(A Top Pick Nov 07/17, Up 10%) Their big thing is drug delivery equipment. They have a lot of things going for them. They had a messy quarter. It is why he prefers to use ETFs for this. It was not a small pull back for them. The acquisition gives them some synergy on costs.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Cameron Hurst

Chief Inve, Equium Capital Manag...

Price Price
$236.220
Owned Owned
Yes

TOP PICK
Becton Dickinson(BDX-N) 

November 2, 2018

They make medical devides (syringes, blood test equipment). After last year's acqusition, there are two cash-flow companies here which excites him. He's owned this for a decade. 1.3% dividend. 10% dividend and price growth. (Analysts’ price target is $270.50)

biotechnology/pharmaceutical
0 0 0 0 0
0 comments

They make medical devides (syringes, blood test equipment). After last year's acqusition, there are two cash-flow companies here which excites him. He's owned this for a decade. 1.3% dividend. 10% dividend and price growth. (Analysts’ price target is $270.50)

biotechnology/pharmaceutical
0 0 0 0 0
0 comments
David Driscoll

President , Liberty Internationa...

Price Price
$235.580
Owned Owned
Yes

PAST TOP PICK
Becton Dickinson(BDX-N) 

October 31, 2018

(A Top Pick Aug 29/18, Up 18%) They do healthcare--hospitals, clinics--as an end-to-end service provider. They give hospital admin the software and provide all the products you'd need, like catheters or surgical equipment. Really they have no competition. Their customers stay loyal. They made a recent acquisition that gives them more international exposure. It doesn't have as much regulatory risk as other healthcare or pharma companies.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments

(A Top Pick Aug 29/18, Up 18%) They do healthcare--hospitals, clinics--as an end-to-end service provider. They give hospital admin the software and provide all the products you'd need, like catheters or surgical equipment. Really they have no competition. Their customers stay loyal. They made a recent acquisition that gives them more international exposure. It doesn't have as much regulatory risk as other healthcare or pharma companies.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Barry Schwartz

CIO & Port, Baskin Wealth Manage...

Price Price
$230.500
Owned Owned
Yes

PAST TOP PICK
Becton Dickinson(BDX-N) 

August 24, 2018

(A top pick June 6/18, up 10%) This stock is showing no signs of consolidation and is in an uptrend. So is continuing to hold it.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments

(A top pick June 6/18, up 10%) This stock is showing no signs of consolidation and is in an uptrend. So is continuing to hold it.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Keith Richards

Portfolio , ValueTrend Wealth Ma...

Price Price
$255.400
Owned Owned
Yes

TOP PICK

A great up trending stock chart.  It is consolidating at the moment with lots of time to grow.  Yield 1.3%.  (Analysts’ price target is $251.11)

biotechnology/pharmaceutical
0 0 0 0 0
0 comments

A great up trending stock chart.  It is consolidating at the moment with lots of time to grow.  Yield 1.3%.  (Analysts’ price target is $251.11)

biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Keith Richards

Portfolio , ValueTrend Wealth Ma...

Price Price
$231.610
Owned Owned
Yes

BUY
Becton Dickinson(BDX-N) 

April 23, 2018

U.S. healthcare in the short-term? He prefers individual stocks over ETFs, starting with Becton Dickinson (and Zimmer Biomet, ZBH-N). In this sector, he prefers medical devices, not drugs which are easy to copy. Becton is a long-term opportunity and a play on demographics.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments

U.S. healthcare in the short-term? He prefers individual stocks over ETFs, starting with Becton Dickinson (and Zimmer Biomet, ZBH-N). In this sector, he prefers medical devices, not drugs which are easy to copy. Becton is a long-term opportunity and a play on demographics.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Barry Schwartz

CIO & Port, Baskin Wealth Manage...

Price Price
$233.020
Owned Owned
Yes

PAST TOP PICK
Becton Dickinson(BDX-N) 

March 28, 2018

(A Top Pick May 19/17, Up 17%) They merged with C.R. Bard, another medical device company, so this has opened doors for them internationally. Dividend growing 10% a year. They continue to acquire and grow. He has owned it for 10 years.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments

(A Top Pick May 19/17, Up 17%) They merged with C.R. Bard, another medical device company, so this has opened doors for them internationally. Dividend growing 10% a year. They continue to acquire and grow. He has owned it for 10 years.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments
David Driscoll

President , Liberty Internationa...

Price Price
$212.430
Owned Owned
Yes

PARTIAL BUY
Becton Dickinson(BDX-N) 

February 21, 2018

He sees this as a good company, but not in his top 25.  Healthcare technology has been very profitable and medical consumables is a niche area.  There is good opportunity to grow through value add like prefilled syringes.    He sees them as a high quality, low cost provider.  

biotechnology/pharmaceutical
0 0 0 0 0
0 comments

He sees this as a good company, but not in his top 25.  Healthcare technology has been very profitable and medical consumables is a niche area.  There is good opportunity to grow through value add like prefilled syringes.    He sees them as a high quality, low cost provider.  

biotechnology/pharmaceutical
0 0 0 0 0
0 comments
David Fingold

VP and Por, Dynamic Funds...

Price Price
$218.700
Owned Owned
Yes

BUY
Becton Dickinson(BDX-N) 

February 13, 2018

They bought C.R. Bard, the Canadian Tire of medical supplies and basically consolidated the industry, giving them tremendous market share and pricing power. They are now the premier company in this space.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments

They bought C.R. Bard, the Canadian Tire of medical supplies and basically consolidated the industry, giving them tremendous market share and pricing power. They are now the premier company in this space.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments
David Baskin

President, Baskin Wealth Manage...

Price Price
$215.400
Owned Owned
Yes

Showing 1 to 15 of 48 entries
Successfully Saved Company
Successfully Saved Company
7+
JOIN THE DISCUSSION
7 comments in the last 7 days